Event Details
Nonviral CRISPR-based knock-in of chimeric antigen receptor transgenes into T cells for cell therapy
Join us for an insightful webinar on the latest advancements in cell and gene therapy, focusing on the innovative Cas9-CLIPT technology.
Cas9-CLIPT (Cleaved, Linearized with Protein Template) is a groundbreaking technology designed to improve the efficiency of genome editing. It involves using a circular plasmid with a single target sequence for the Cas9 ribonucleoprotein (RNP). During manufacturing, the Cas9-RNP binds and cleaves the Nanoplasmid, linearizing the double-stranded DNA (dsDNA) in vitro. This linearized template, bound to Cas9-RNP, is then delivered to cells to promote precise knock-in via homology-directed repair. This method significantly enhances the precision and efficiency of CAR T cell production.
Key Takeaways:
-Gain insights into cutting-edge genome editing technologies
-Discover strategies to improve nonviral manufacturing processes
-Learn practical applications and benefits of Cas9-CLIPT in CAR T cell manufacturing
-And more
Speakers
|
Krishanu Saha, PhD Krishanu Saha, PhD is a Professor and the Retina Research Foundation Kathryn and Latimer Murfee Chair at the University of Wisconsin-Madison. He leads pioneering research in nonviral genome editing methods for stem cells and somatic cells. Dr. Saha is also involved in large-scale collaborative projects, including the NSF Center for Cell Manufacturing Technologies and the NIH Somatic Cell Genome Editing Consortium. His work spans engineering, medicine, and ethics, contributing significantly to the field of therapeutic genome editing. |
|
Max Sellman Max Sellman is Senior Product Manager, Gene Editing, at Aldevron focusing on gene editing protein products and custom services since 2017. Prior to Aldevron, Max was a Business Development and Alliance Management Lead for BioTechnique, a GMP fill/finish CMO. Max holds a bachelor’s degree from the University of Wisconsin in Genetics and Life Sciences Communication. |